• National
  • Politics
  • Valley
  • Opinion
  • Money
  • Sports
  • Culture & Lifestyle

  • National
    • Madhesh Province
    • Lumbini Province
    • Bagmati Province
    • National Security
    • Koshi Province
    • Gandaki Province
    • Karnali Province
    • Sudurpaschim Province
  • Politics
  • Valley
    • Kathmandu
    • Lalitpur
    • Bhaktapur
  • Opinion
    • Columns
    • As it is
    • Letters
    • Editorial
    • Cartoon
  • Money
  • Sports
    • Cricket
    • Football
    • International Sports
  • Culture & Lifestyle
    • Arts
    • Brunch with the Post
    • Movies
    • Life & Style
    • Theater
    • Entertainment
    • Books
    • Fashion
  • Health
  • Food
    • Recipes
  • Travel
  • Investigations
  • Climate & Environment
  • World
  • Science & Technology
  • Interviews
  • Visual Stories
  • Crosswords & Sudoku
  • Horoscope
  • Forex
  • Corrections
  • Letters to the Editor
  • Today's ePaper
Saturday, September 20, 2025

Without Fear or FavourUNWIND IN STYLE

23.12°C Kathmandu
Air Quality in Kathmandu: 59
300+Hazardous
0-50Good
51-100Moderate
101-150Unhealty for Sensitive Groups
151-200Unhealthy
201-300Very Unhealthy
Sat, Sep 20, 2025
23.12°C Kathmandu
Air Quality in Kathmandu: 59
  • What's News :

  • Constitution at a critical juncture
  • Reform in major parties
  • Poor market monitoring
  • Repair of offices damaged during protests
  • Art exhibition

World

Omicron-specific Sinopharm, Sinovac Covid vaccine candidates cleared for clinical trial

Scientists worldwide are racing to study upgraded injections against Omicron, as data indicated that antibodies elicited by vaccines based on older strains show weaker activity to neutralise the highly transmissible variant. Omicron-specific Sinopharm, Sinovac Covid vaccine candidates cleared for clinical trial
A vial labelled “Sinopharm Covid-19 Vaccine” is seen in this illustration taken January 16, 2022. Reuters
bookmark
  • facebook
  • twitter
  • Whatsapp
  • mail
Reuters
Published at : April 18, 2022
Updated at : April 18, 2022 11:53
Beijing

Covid-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday.

Scientists worldwide are racing to study upgraded injections against Omicron, as data indicated that antibodies elicited by vaccines based on older strains show weaker activity to neutralise the highly transmissible variant.

The two candidates from units of Sinopharm subsidiary China National Biotec Group (CNBG) and one from Sinovac contain inactivated or “killed” coronavirus and are similar to vaccines that the companies are supplying in China and overseas, the companies said in statements.

The Sinopharm candidates will be tested as boosters in adults who have already received two or three vaccine doses, CNBG said. It did not specify which vaccine products the trial participants would have received before taking the experimental booster, or how many subjects would be recruited.

Sinovac said it will push forward studies in its existing CoronaVac vaccine’s protection against emerging variants.

A Chinese study showed that a fourth dose of BBIBP-CorV, an existing Sinopharm Covid vaccine, did not significantly lift antibody levels against Omicron when administered six months after a third booster dose to a regular two-dose regimen.

While the fourth dose restored antibody levels to around the peaks that followed the third dose, researchers said new vaccines would offer a better alternative as future boosters.


Related News

Cyberattack disrupts European airports including Heathrow, Brussels
Russian jets enter Estonia’s airspace in latest test for NATO
Trump to impose $100,000 fee per year for H-1B visas, in likely blow to tech
British couple freed by Taliban after Qatari mediation, official says
Feathers fly in dispute over Ambani zoo’s pursuit of rare parrot
US casts 6th veto at United Nations over war in Gaza

Most Read from World

South Korea sees marriages fall by half, births down two-thirds, more foreign spouses
Trump to impose $100,000 fee per year for H-1B visas, in likely blow to tech
Sri Lanka resumes key highway project with $500 million new Chinese funding
Boeing, Honeywell sued by Air India crash victim families
Qatar, US nearing defence deal after Israel's attack in Doha, Rubio says

Editor's Picks

How misinformation fuelled panic during Gen Z uprising
At 86, Spanish Carlos Soria sets sights on Manaslu
She made history as first woman chief justice of Nepal. Now as PM
3 Gorkha youths killed in Gen Z protests, leaving families and dreams shattered
Nepal’s immunisation on the brink after vaccine stocks gutted in arsons

E-PAPER | September 20, 2025

  • Read ePaper Online
ABOUT US
  • About the Post
  • Masthead
  • Editorial Standards & Integrity
  • Workplace Harassment Policy
  • Privacy Policy
READ US
  • Home Delivery
  • ePaper
CONTACT US
  • Write for the Post
  • Letters to the Editor
  • Advertise in the Post
  • Work for the Post
  • Send us a tip
INTERACT WITH US
  • Twitter
  • Facebook
  • Instagram
OUR SISTER PUBLICATIONS
  • eKantipur
  • saptahik
  • Nepal
  • Nari
  • Radio Kantipur
  • Kantipur TV
© 2025 www.kathmandupost.com
  • Privacy Policy
Top